Myriad Seeks To Diversify While Remaining Aggressive On BRCA Testing Market
This article was originally published in The Gray Sheet
While the genetics firm is not wavering in its legal effort to protect its BRCA gene testing dominance, it is diversifying in response to inevitable competition, with a focus on a multigene panel and companion diagnostics.
You may also be interested in...
FDA approved Abbott’s MitraClip to treat mitral regurgitation and Allergan’s Juvéderm Voluma XC facial filler to temporary correct volume-loss. Hepatitis C testing will be mandatory in New York. More news.
With the Oct. 15 launch of the BRCAvantage genetic test, Quest Diagnostics Inc. became the latest entrant into the now-competitive marketplace for BRCA diagnostic testing for the likelihood of inheriting breast or ovarian cancer.
Myriad president Mark Capone made it clear that the company will use its proprietary database of genetic variants on the BRCA1 and BRCA2 genes to try and fend off cheaper competition after the BRACAnalysis test’s method patents are expired, or if they are overturned in court.